Natco Pharma Valuation
| NATCOPHARM | 1,376 38.05 2.84% |
At this time, the firm appears to be overvalued. Natco Pharma Limited secures a last-minute Real Value of USD1114.16 per share. The latest price of the firm is USD1375.5. Our model forecasts the value of Natco Pharma Limited from analyzing the firm fundamentals such as Current Valuation of 223.82 B, profit margin of 0.43 %, and Return On Equity of 0.31 as well as examining its technical indicators and probability of bankruptcy.
Price Book 3.4457 | Enterprise Value 223.8 B | Enterprise Value Ebitda 8.749 | Price Sales 5.3983 | Forward PE 16.8634 |
Overvalued
Today
Please note that Natco Pharma's price fluctuation is very steady at this time. Calculation of the real value of Natco Pharma Limited is based on 3 months time horizon. Increasing Natco Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Natco Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Natco Stock. However, Natco Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1375.5 | Real 1114.16 | Hype 1366.65 | Naive 1374.32 |
The intrinsic value of Natco Pharma's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Natco Pharma's stock price.
Estimating the potential upside or downside of Natco Pharma Limited helps investors to forecast how Natco stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Natco Pharma more accurately as focusing exclusively on Natco Pharma's fundamentals will not take into account other important factors: Natco Pharma Cash |
|
Natco Pharma Total Value Analysis
Natco Pharma Limited is now forecasted to have takeover price of 223.82 B with market capitalization of 246.37 B, debt of 3.86 B, and cash on hands of 4.14 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Natco Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
223.82 B | 246.37 B | 3.86 B | 4.14 B |
Natco Pharma Investor Information
About 51.0% of the company outstanding shares are owned by corporate insiders. The book value of Natco Pharma was now reported as 399.14. The company recorded earning per share (EPS) of 108.66. Natco Pharma Limited last dividend was issued on the 27th of November 2024. The entity had 5:1 split on the 26th of November 2015. Based on the key measurements obtained from Natco Pharma's financial statements, Natco Pharma Limited is performing exceptionally good at this time. It has a great probability to report excellent financial results in January.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 13.1 B | 12.5 B |
|
| |||||
| Operating Income | 27.3 B | 26 B |
|
|
Natco Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Natco Pharma has an asset utilization ratio of 57.95 percent. This signifies that the Company is making USD0.58 for each dollar of assets. An increasing asset utilization means that Natco Pharma Limited is more efficient with each dollar of assets it utilizes for everyday operations.Natco Pharma Ownership Allocation
Natco Pharma Limited maintains a total of 179.11 Million outstanding shares. Natco Pharma Limited holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Natco Pharma Profitability Analysis
The company reported the revenue of 40.02 B. Net Income was 13.88 B with profit before overhead, payroll, taxes, and interest of 20.54 B.About Natco Pharma Valuation
An absolute valuation paradigm, as applied to Natco Stock, attempts to find the value of Natco Pharma Limited based on its fundamental and basic technical indicators. By analyzing Natco Pharma's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Natco Pharma's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Natco Pharma. We calculate exposure to Natco Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Natco Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 31.4 B | 33 B |
Natco Pharma Quarterly Retained Earnings |
|
Complementary Tools for Natco Stock analysis
When running Natco Pharma's price analysis, check to measure Natco Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Natco Pharma is operating at the current time. Most of Natco Pharma's value examination focuses on studying past and present price action to predict the probability of Natco Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Natco Pharma's price. Additionally, you may evaluate how the addition of Natco Pharma to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |